Ajanta Pharma Ltd Capacity Expansion and Strategic Moves

₹92 Cr Pithampur facility to triple liquid formulations to 18 Mn bottles/year (from 6 Mn), completion Q1 FY26; current ops at 175% utilization. Established Ajanta Pharma Ireland Ltd (Jan 13); FTSE All World Index inclusion (~$23.8 Mn inflows); Q3 EBITDA +19% to ₹382 Cr (27.8% margin). 49 ANDAs commercialized, 19 pending US FDA approval.